Resource Utilization and Survival Among Medicare Patients with Advanced Liver Disease

Digestive Diseases and Sciences

Volumn 60, Issue 2, 2015, Pages 320-332

  Otgonsuren, Munkhzul ^a   Henry, Linda ^a   Hunt, Sharon ^a   Venkatesan, Chapy ^b   Mishra, Alita ^b   Younossi, Zobair M ^a,b  

^a BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^b INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

Advanced liver disease; Medicare; Mortality; Predictors; Resource utilization

Indexed keywords

AGED; AMBULATORY CARE; COMORBIDITY; CROSS-SECTIONAL STUDY; ECONOMICS; HEALTH CARE PLANNING; HOSPITAL COST; HUMAN; INTENSIVE CARE; LENGTH OF STAY; LIVER DISEASES; MALE; MEDICARE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PARACENTESIS; RETROSPECTIVE STUDY; RISK; RISK FACTOR; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; UNITED STATES; UTILIZATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMBULATORY CARE; COMORBIDITY; CROSS-SECTIONAL STUDIES; HEALTH RESOURCES; HOSPITAL COSTS; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE; LENGTH OF STAY; LINEAR MODELS; LIVER DISEASES; LOGISTIC MODELS; MALE; MEDICARE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PARACENTESIS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84925028249     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3318-9     Document Type: Article

References (37)

1. Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63:844–855. doi:10.1136/gutjnl-2013-306627.
2. Planas R, Montoliu S, Balleste B, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol. 2006;4:1385–1394.
3. McAdam-Marx C, McGarry LJ, Hane CA, Biskupiak J, Deniz B, Brixner DI. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm. 2011;17:531–546.
4. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53:397–417.
5. Giannini EG, Cucchetti A, Erroi V, Garuti F, Odaldi F, Trevisani F. Surveillance for early diagnosis of hepatocellular carcinoma: how best to do it? World J Gastroenterol. 2013;19:8808–8821.
6. Ngamruengphong S, Patel T. Molecular evolution of genetic susceptibility to hepatocellular carcinoma. Dig Dis Sci. 2014;59:986–991. doi:10.1007/s10620-013-2984-3.
7. Ding J, Wang H. Multiple interactive factors in hepatocarcinogenesis. Cancer. 2013. doi:10.1016/j.canlet.2013.12.024.
8. Triolo M, Corte CD, Colombo M. Impact of HBV therapy on the incidence of hepatocellular carcinoma. Liver Int. 2014;34:139–145. doi:10.1111/liv.12394.
9. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res. 2007;37:S88–S94.
10. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264–1273.e1. doi:10.1053/j.gastro.2011.12.061.
11. Kanwal F, Hoang T, Kramer JR, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 2011;140:1182–1188.e1. doi:10.1053/j.gastro.2010.12.032.
12. MMWR Recommendations and Reports. Recommendations for the identification of chronic hepatitis C infection among persons born during 1945–1965. Recomm Rep. 2012;61:1–32. http://www.cdc.gov/mmwr/pdf/rr/rr6104.pdf. (March 10, 2013).
13. Davis GL, Roberts WL. The healthcare burden imposed by liver disease in aging baby boomers. Curr Gastroenterol Rep. 2010;12:1–6. doi:10.1007/s11894-009-0087-2.
14. Younossi ZM, Stepanova M, Mishra A, Venkatesan C, Henry L, Hunt S. The impact of chronic hepatitis C on resource utilisation and in-patient mortality for Medicare beneficiaries between 2005 and 2010. Aliment Pharmacol Ther. 2013;38:1065–1075. doi:10.1111/apt.12485.
15. Younossi ZM, Singer ME, Mir HM, Henry L, Hunt S. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol. 2013. doi:10.1016/j.jhep.2013.11.009.
16. Medicare Payment Advisory Committee. Health Care Spending and the Medicare program. 2012. http://www.medpac.gov/documents/Jun12DataBookEntireReport.pdf. (Last accessed on July 20, 2013).
17. McWilliams JM, Landon BE, Chernew ME. Changes in health care spending and quality for Medicare beneficiaries associated with a commercial ACO contract. JAMA. 2013;310:829–836. doi:10.1001/jama.2013.276302.
18. Orszag PR, Ellis P. The challenge of rising health care costs—a view from the congressional budget office. N Engl J Med. 2007;357:1793–1795.
19. Chernew ME, Baicker K, Hsu J. The specter of financial armageddon—health care and federal debt in the United States. N Engl J Med. 2010;362:1166–1168.
20. Chernew ME, Hirth RA, Cutler DM. Increased spending on health care: longterm implications for the nation. Health Aff (Millwood). 2009;28:1253–1255.
21. Engelberg Center for Health Care Reform. Bending the Curve: Effective Steps to Address Long-Term Health Care Spending Growth. Brookings Institution; 2009. http://www.brookings.edu/reports/2009/0901_btc.aspx.
22. Centers for Medicare and Medicaid Services. Standard Analytical Files. http://www.cms.hhs.gov/IdentifiableDataFiles/02_StandardAnalyticalFiles.asp. (Accessed July 20, 2014).
23. Consumer price index inflation calculator. US Department of Labor, Bureau of Labor Statistics. http://www.bls.gov/bls/inflation.htm. (Accessed July 20, 2014).
24. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.
25. Kirstein MM, Vogel A. The pathogenesis of hepatocellular carcinoma. Dig Dis. 2014;32:545–553. doi:10.1159/000360499.
26. Heidelbaugh JJ, Bruderly M. Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation. Am Fam Physician. 2006;74:756–762.
27. Heidelbaugh JJ, Sherbondy M. Cirrhosis and chronic liver failure: part II. Complications and treatment. Am Fam Physician. 2006;74:767–776.
28. US Burden of Disease Collaborators. The state of US health, 1990–2010. Burden of diseases, injuries, and risk factors. JAMA. 2013. doi:10.1001/jama.2013.13805.
29. US Cancer Statistics Working Group. United States Cancer Statistics: 1999–2010 Incidence and Mortality Web-based Report. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2013. www.cdc.gov/uscs.
30. Heydtmann M, McDonald SA. Survival and re-admission of patients admitted with alcoholic liver disease to a West of Scotland hospital. Scott Med J. 2013;58:134–138. doi:10.1177/0036933013490381.
31. Lin OS, Keeffe EB, Sanders GD, Owens DK. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther. 2004;19:1159–1172.
32. Stepanova M, Wai H, Saab S, Mishra A, Venkatesan C, Younossi ZM. The portrait of an adult liver transplant recipient in the United States from 1987 to 2013. JAMA Intern Med. 2014. doi:10.1001/jamainternmed.2014.2903.
33. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health. 2000;90:1562–1569.
34. Gordon SC, Pockros PJ, Terrault NA, et al. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. Hepatology. 2012;56:1651–1660. doi:10.1002/hep.25842.
35. Lerschmacher O, Koch A, Streetz K, Trautwein C, Tacke F. Management of decompensated liver cirrhosis in the intensive care unit. Med Klin Intensivmed Notfmed. 2013;108:646–656. doi:10.1007/s00063-013-0259-6.
36. Ratib S, Fleming KM, Crooks CJ, Aithal GP, West J. 1 and 5 year survival estimates for people with cirrhosis of the liver in England, 1998–2009: a large population study. J Hepatol. 2014;60:282–289. doi:10.1016/j.jhep.2013.09.027.
37. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464–470.